CoGenesys is a biopharmaceutical company focused on developing innovative long-acting medicines across broad therapeutic areas.
Our goal, as an early-stage drug development
organization, is to execute a business plan unique within the
pharmaceutical industry: to rapidly and efficiently generate medically
important, stable, long-acting bio-therapeutics, which are then
available for sale, license or further partner-funded development
following early-stage demonstration of safety and proof of concept in
man.
At CoGenesys, we are applying a proprietary and
clinically validated technology that allows the improvement and
expanded use of many known and clinically established therapeutic
peptides and proteins as well as the creation of new medicines from
known pharmaceutically relevant peptides. Without the benefit of our
technology, these peptides and proteins have numerous shortcomings
including poor bio-availability, the need for frequent dosing, and
unwanted side-effect profiles.
CoGenesys’ highly experienced management and
development teams have a significant track record in translating early
drug opportunities into clinically-proven candidates for the
pharmaceutical market. Our state of the art research and manufacturing
facility is fully equipped, supporting both GLP development and cGMP
manufacture of biologics. We have capitalized on the depth of our
pipeline and the breadth of our technology to develop drug candidates
that will address a broad spectrum of unmet needs including diabetes,
cardiovascular disease, and enzyme replacement therapy, among others.
We currently have several well-advanced product development programs
including our lead clinical candidate Cardeva, a long-acting
natriuretic peptide being developed for outpatient treatment of chronic
heart failure. The second program, Neugranin, a long-acting form of
granulocyte colony stimulating factor (GCSF), is being readied for
clinical development as an agent initially for the treatment of febrile
neutropenia associated with chemotherapy.
